Chitosan/gelatin hydrogel as immunoisolative matrix for injectable bioartificial pancreas

Kai Chiang Yang, Chang Chin Wu, Feng Huei Lin, Zhi Qi, Tzong Fu Kuo, Yung Hsin Cheng, Moon Pei Chen, Shoichiro Sumi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: The feasibility of using chitosan/gelatin hydrogel as immunoisolative matrix to provide an additional protection to the microencapsulated islet cells was demonstrated in this study. We hope that the use of hydrogel can extend the functional longevity of microencapsulated islet cells during xenotransplantation. Methods: Chitosan/gelatin solution with glycerol 2-phosphate disodium salt hydrate was prepared and utilized as a cell carrier. The biocompatibility of the chitosan/gelatin hydrogel was first established by using a mouse insulinoma cell line, NIT-1. Insulinoma cells were encapsulated in agarose as microspheres and then macroencapsulated in chitosan/gelatin hydrogel. In vitro cell activity, material-mediated cytotoxicity, cytokine-mediated cytotoxicity assay, and insulin secreting profiles of insulinoma/agarose microspheres macroencapsulated in chitosan/gelatin hydrogel were analyzed. For in vivo study, insulinoma/agarose microspheres with chitosan/gelatin solution was applied as an injectable bioartificial pancreas (BAPs). Insulinoma/agarose microspheres suspended in phosphate-buffered saline or in chitosan/gelatin solution was injected into the subcutaneous layer of diabetic rats. Non-fasting blood glucose (NFBG) concentration of rat was measured perioperatively. After pre-determined intervals, the chitosan/gelatin hydrogel containing insulinoma/agarose microspheres was retrieved for histologic examinations. Results: Insulinoma/agarose microspheres macroencapsulated in hydrogel revealed functional activity and secreted insulin continually for 60 days in vitro. Chitosan/gelatin hydrogel was not cytotoxic to islet cells, and in contrast, the hydrogel showed cytoprotective effects against cytokine-mediated cytotoxicity. The NFBG of diabetic rats transplanted with free insulinoma/agarose microspheres was decreased to euglycemia but restored to hyperglycemia in 15 days. Contrarily, the NFBG of rats transplanted with insulinoma/agarose microspheres with hydrogel remained euglycemic for 42 days. Histologic sections revealed that the fibrous tissue envelopment and the infiltrated immune-related cells contributed to the dysfunction of BAPs. Conclusions: This study indicates that using chitosan/gelatin hydrogel as a cell carrier is feasible and can provide an additional protection for the microencapsulated islet cells during xenotransplantation.

Original languageEnglish
Pages (from-to)407-416
Number of pages10
JournalXenotransplantation
Volume15
Issue number6
DOIs
Publication statusPublished - Nov 2008
Externally publishedYes

Fingerprint

Hydrogel
Chitosan
Gelatin
Insulinoma
Pancreas
Microspheres
Sepharose
Injections
Islets of Langerhans
Blood Glucose
Heterologous Transplantation
Phosphates
Insulin
Cytokines
Hyperglycemia
Glycerol
Salts
Cell Line

Keywords

  • Hydrogel
  • Immunoisolation
  • Type 1 diabetes
  • Xenotransplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Chitosan/gelatin hydrogel as immunoisolative matrix for injectable bioartificial pancreas. / Yang, Kai Chiang; Wu, Chang Chin; Lin, Feng Huei; Qi, Zhi; Kuo, Tzong Fu; Cheng, Yung Hsin; Chen, Moon Pei; Sumi, Shoichiro.

In: Xenotransplantation, Vol. 15, No. 6, 11.2008, p. 407-416.

Research output: Contribution to journalArticle

Yang, Kai Chiang ; Wu, Chang Chin ; Lin, Feng Huei ; Qi, Zhi ; Kuo, Tzong Fu ; Cheng, Yung Hsin ; Chen, Moon Pei ; Sumi, Shoichiro. / Chitosan/gelatin hydrogel as immunoisolative matrix for injectable bioartificial pancreas. In: Xenotransplantation. 2008 ; Vol. 15, No. 6. pp. 407-416.
@article{b98c33ed42bf4239976c8d4058580c42,
title = "Chitosan/gelatin hydrogel as immunoisolative matrix for injectable bioartificial pancreas",
abstract = "Background: The feasibility of using chitosan/gelatin hydrogel as immunoisolative matrix to provide an additional protection to the microencapsulated islet cells was demonstrated in this study. We hope that the use of hydrogel can extend the functional longevity of microencapsulated islet cells during xenotransplantation. Methods: Chitosan/gelatin solution with glycerol 2-phosphate disodium salt hydrate was prepared and utilized as a cell carrier. The biocompatibility of the chitosan/gelatin hydrogel was first established by using a mouse insulinoma cell line, NIT-1. Insulinoma cells were encapsulated in agarose as microspheres and then macroencapsulated in chitosan/gelatin hydrogel. In vitro cell activity, material-mediated cytotoxicity, cytokine-mediated cytotoxicity assay, and insulin secreting profiles of insulinoma/agarose microspheres macroencapsulated in chitosan/gelatin hydrogel were analyzed. For in vivo study, insulinoma/agarose microspheres with chitosan/gelatin solution was applied as an injectable bioartificial pancreas (BAPs). Insulinoma/agarose microspheres suspended in phosphate-buffered saline or in chitosan/gelatin solution was injected into the subcutaneous layer of diabetic rats. Non-fasting blood glucose (NFBG) concentration of rat was measured perioperatively. After pre-determined intervals, the chitosan/gelatin hydrogel containing insulinoma/agarose microspheres was retrieved for histologic examinations. Results: Insulinoma/agarose microspheres macroencapsulated in hydrogel revealed functional activity and secreted insulin continually for 60 days in vitro. Chitosan/gelatin hydrogel was not cytotoxic to islet cells, and in contrast, the hydrogel showed cytoprotective effects against cytokine-mediated cytotoxicity. The NFBG of diabetic rats transplanted with free insulinoma/agarose microspheres was decreased to euglycemia but restored to hyperglycemia in 15 days. Contrarily, the NFBG of rats transplanted with insulinoma/agarose microspheres with hydrogel remained euglycemic for 42 days. Histologic sections revealed that the fibrous tissue envelopment and the infiltrated immune-related cells contributed to the dysfunction of BAPs. Conclusions: This study indicates that using chitosan/gelatin hydrogel as a cell carrier is feasible and can provide an additional protection for the microencapsulated islet cells during xenotransplantation.",
keywords = "Hydrogel, Immunoisolation, Type 1 diabetes, Xenotransplantation",
author = "Yang, {Kai Chiang} and Wu, {Chang Chin} and Lin, {Feng Huei} and Zhi Qi and Kuo, {Tzong Fu} and Cheng, {Yung Hsin} and Chen, {Moon Pei} and Shoichiro Sumi",
year = "2008",
month = "11",
doi = "10.1111/j.1399-3089.2008.00503.x",
language = "English",
volume = "15",
pages = "407--416",
journal = "Xenotransplantation",
issn = "0908-665X",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Chitosan/gelatin hydrogel as immunoisolative matrix for injectable bioartificial pancreas

AU - Yang, Kai Chiang

AU - Wu, Chang Chin

AU - Lin, Feng Huei

AU - Qi, Zhi

AU - Kuo, Tzong Fu

AU - Cheng, Yung Hsin

AU - Chen, Moon Pei

AU - Sumi, Shoichiro

PY - 2008/11

Y1 - 2008/11

N2 - Background: The feasibility of using chitosan/gelatin hydrogel as immunoisolative matrix to provide an additional protection to the microencapsulated islet cells was demonstrated in this study. We hope that the use of hydrogel can extend the functional longevity of microencapsulated islet cells during xenotransplantation. Methods: Chitosan/gelatin solution with glycerol 2-phosphate disodium salt hydrate was prepared and utilized as a cell carrier. The biocompatibility of the chitosan/gelatin hydrogel was first established by using a mouse insulinoma cell line, NIT-1. Insulinoma cells were encapsulated in agarose as microspheres and then macroencapsulated in chitosan/gelatin hydrogel. In vitro cell activity, material-mediated cytotoxicity, cytokine-mediated cytotoxicity assay, and insulin secreting profiles of insulinoma/agarose microspheres macroencapsulated in chitosan/gelatin hydrogel were analyzed. For in vivo study, insulinoma/agarose microspheres with chitosan/gelatin solution was applied as an injectable bioartificial pancreas (BAPs). Insulinoma/agarose microspheres suspended in phosphate-buffered saline or in chitosan/gelatin solution was injected into the subcutaneous layer of diabetic rats. Non-fasting blood glucose (NFBG) concentration of rat was measured perioperatively. After pre-determined intervals, the chitosan/gelatin hydrogel containing insulinoma/agarose microspheres was retrieved for histologic examinations. Results: Insulinoma/agarose microspheres macroencapsulated in hydrogel revealed functional activity and secreted insulin continually for 60 days in vitro. Chitosan/gelatin hydrogel was not cytotoxic to islet cells, and in contrast, the hydrogel showed cytoprotective effects against cytokine-mediated cytotoxicity. The NFBG of diabetic rats transplanted with free insulinoma/agarose microspheres was decreased to euglycemia but restored to hyperglycemia in 15 days. Contrarily, the NFBG of rats transplanted with insulinoma/agarose microspheres with hydrogel remained euglycemic for 42 days. Histologic sections revealed that the fibrous tissue envelopment and the infiltrated immune-related cells contributed to the dysfunction of BAPs. Conclusions: This study indicates that using chitosan/gelatin hydrogel as a cell carrier is feasible and can provide an additional protection for the microencapsulated islet cells during xenotransplantation.

AB - Background: The feasibility of using chitosan/gelatin hydrogel as immunoisolative matrix to provide an additional protection to the microencapsulated islet cells was demonstrated in this study. We hope that the use of hydrogel can extend the functional longevity of microencapsulated islet cells during xenotransplantation. Methods: Chitosan/gelatin solution with glycerol 2-phosphate disodium salt hydrate was prepared and utilized as a cell carrier. The biocompatibility of the chitosan/gelatin hydrogel was first established by using a mouse insulinoma cell line, NIT-1. Insulinoma cells were encapsulated in agarose as microspheres and then macroencapsulated in chitosan/gelatin hydrogel. In vitro cell activity, material-mediated cytotoxicity, cytokine-mediated cytotoxicity assay, and insulin secreting profiles of insulinoma/agarose microspheres macroencapsulated in chitosan/gelatin hydrogel were analyzed. For in vivo study, insulinoma/agarose microspheres with chitosan/gelatin solution was applied as an injectable bioartificial pancreas (BAPs). Insulinoma/agarose microspheres suspended in phosphate-buffered saline or in chitosan/gelatin solution was injected into the subcutaneous layer of diabetic rats. Non-fasting blood glucose (NFBG) concentration of rat was measured perioperatively. After pre-determined intervals, the chitosan/gelatin hydrogel containing insulinoma/agarose microspheres was retrieved for histologic examinations. Results: Insulinoma/agarose microspheres macroencapsulated in hydrogel revealed functional activity and secreted insulin continually for 60 days in vitro. Chitosan/gelatin hydrogel was not cytotoxic to islet cells, and in contrast, the hydrogel showed cytoprotective effects against cytokine-mediated cytotoxicity. The NFBG of diabetic rats transplanted with free insulinoma/agarose microspheres was decreased to euglycemia but restored to hyperglycemia in 15 days. Contrarily, the NFBG of rats transplanted with insulinoma/agarose microspheres with hydrogel remained euglycemic for 42 days. Histologic sections revealed that the fibrous tissue envelopment and the infiltrated immune-related cells contributed to the dysfunction of BAPs. Conclusions: This study indicates that using chitosan/gelatin hydrogel as a cell carrier is feasible and can provide an additional protection for the microencapsulated islet cells during xenotransplantation.

KW - Hydrogel

KW - Immunoisolation

KW - Type 1 diabetes

KW - Xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=58149085104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149085104&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3089.2008.00503.x

DO - 10.1111/j.1399-3089.2008.00503.x

M3 - Article

VL - 15

SP - 407

EP - 416

JO - Xenotransplantation

JF - Xenotransplantation

SN - 0908-665X

IS - 6

ER -